References of "Evrard, Brigitte"
     in
Bookmark and Share    
Peer Reviewed
See detailNMR in the Pharmaceutical and Biomedical areas for identification and quantification of drugs and metabolomics applications
LAMBERT, Vincent ULg; Dufour, Gilles ULg; Chiap, Patrice ULg et al

Conference (2014, June 23)

Nuclear Magnetic Resonance (NMR) is probably, with mass spectrometry, the most powerful analytical tool for the structural determination of organic compounds. For a long time and due to technical ... [more ▼]

Nuclear Magnetic Resonance (NMR) is probably, with mass spectrometry, the most powerful analytical tool for the structural determination of organic compounds. For a long time and due to technical limitations, the main applications of NMR were focused on chemistry (organic, inorganic and medicinal chemistry) or biochemistry (i.e. proteins and proteins ligands analysis). Indeed, despite of very interesting potential in terms of structural information, reproducibility, specificity, quantification, NMR suffered of a lack of sensitivity and sometime of resolution in the case of complex mixture analysis in comparison with other technics. However, since several years, important technical improvements such as huge increase in sensitivity, hyphenation of NMR with LC system, automation and development of 2D and presaturation sequences have opened new putative applications for NMR, specifically in the pharmaceutical and biomedical areas. Then, beside the mass and chromatographic technics classically used for drug analysis, NMR represents an interesting and complementary tool for many applications. In this presentation, we will describe some NMR applications related to the pharma area. Starting from the identification of xenobiotic metabolites by coupling LC-SPE-NMR data with LC-MS/MS results, quantification of cyclodextrines in complex media, identification of illicit compounds, we will finish with our recent metabolomics NMR developments. [less ▲]

Detailed reference viewed: 12 (3 ULg)
See detailImpact of the Structure of Biocompatible Aliphatic Polycarbonate on siRNA Transfection Ability
Frère, Antoine ULg; Kawalec, Michal; Tempelaar, Sarah et al

Art & humanitie (2014)

Detailed reference viewed: 20 (6 ULg)
Full Text
Peer Reviewed
See detailTowards a real time release approach for manufacturing tablets using NIR spectroscopy
Pestieau, Aude ULg; Krier, Fabrice ULg; Thoorens, Grégory et al

in Journal of Pharmaceutical & Biomedical Analysis (2014)

Detailed reference viewed: 22 (7 ULg)
See detailPolyplexes Targeting Angiogenesis in Cancer
Frère, Antoine ULg; Peixoto, Paul ULg; Kawalec, Michal et al

Poster (2014, April)

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailDevice-based controlled local delivery of anastrozol into peritoneal cavity: in vitro and in vivo evaluation
Krier, Fabrice ULg; Riva, Raphaël ULg; Defrère, Sylvie et al

in Journal of Drug Delivery Science and Technology [=JDDST] (2014), 24(2), 198-204

Local treatment using drug loaded implants allows decreasing seric concentrations of the active ingredient with the purpose of limiting side effects and reaching perfect observance. Nowadays, some ... [more ▼]

Local treatment using drug loaded implants allows decreasing seric concentrations of the active ingredient with the purpose of limiting side effects and reaching perfect observance. Nowadays, some diseases are already treated with implants, but generally, by subcutaneous or intra vaginal implantation. In this work, a new implant device dedicated to the intra-peritoneal cavity was developed. For this purpose, a core-membrane polymer implant was selected. We propose an original method to determine the most appropriate membrane to control the release based on the use of Franz cells. The ability of the implant to release a constant quantity of an active ingredient will be assessed by testing implants in vitro. Finally, intra peritoneal cavity and subcutaneous in vivo implantation has been achieved in order to confirm the controlled and local release of the active ingredient. [less ▲]

Detailed reference viewed: 39 (7 ULg)
Full Text
See detailDevelopment of anti-HPV lipoplexes for the treatment of cervical cancer
Lechanteur, Anna ULg; Furst, Tania ULg; Evrard, Brigitte ULg et al

Conference (2013, December 03)

Detailed reference viewed: 11 (4 ULg)
See detailThe intracellular fate of polycarbonate Polyplexes modulates the efficacy of siRNA
Frère, Antoine ULg; Kawalec, Michal; Peixoto, Paul ULg et al

Poster (2013, December)

Detailed reference viewed: 14 (1 ULg)
Full Text
See detailDevelopment of anti-HPV lipoplexes for the treatment of cervical cancer
Lechanteur, Anna ULg; Furst, Tania ULg; Evrard, Brigitte ULg et al

Conference (2013, October 17)

Detailed reference viewed: 14 (5 ULg)
See detailDevice-based controlled local delivery for the treatment of peritoneal pathologies
Riva, Raphaël ULg; Krier, Fabrice; Defrère, Sylvie et al

Poster (2013, August 18)

This contribution aims at reporting the developpment of a controlled drug delivery system (DDS) dedicated to the treatment of intra-peritoneal pathologies, especially endometriosis. At present time ... [more ▼]

This contribution aims at reporting the developpment of a controlled drug delivery system (DDS) dedicated to the treatment of intra-peritoneal pathologies, especially endometriosis. At present time, endometriosis is generally treated by daily oral absorption of drug with the purpose to improve the life quality of patients by the reduction of the pain caused by endometrial lesions. Nevertheless, deleterious side-effects, mainly infertility, are observed as a consequence of the important amount of absorbed active principle. One main advantage of controlled drug delivery devices, e.g. polymer implants, is to maintain sustained drug release over a prolonged period of time thereby eliminating fluctuations in the drug plasma concentration. Moreover, DDS allows a local release of the drug at a specific area, which significantly decreases the active principle concentration in the body and limits side-effects. The peritoneal cavity is a convenient site for the implantation of a DDS against endometriosis because large parts of lesion are localized in this region. At our knowledge, no application of an implant dedicated to the treatment of endometriosis is reported in the literature, whereas the local controlled release of an active principle presents several advantages compared to systemic administration. In this study, anastrozole (2,2’-[5-1H-1,2,4-triazole-1-yl-methyl)-1,3-phenylene]bis(2-methylpropiononitrile)), a well-known aromatase-inhibiting drug, was selected as active molecule. Typically, two non-biodegradable polymers were tested for the elaboration of an anastrozole loaded intra-peritoneal implant, namely polydimethylsiloxane (PDMS) and poly(ethylene-co-vinyl acetate) (EVA). As preliminary research, the ‘in vivo’ biocompatibility of PDMS and EVA in the intra-peritoneal cavity was confirmed by implantation of PDMS and EVA rod-shaped implants in rats. The kinetic of release was determined ‘in vitro’ and confirmed ‘in vivo’. Besides, the efficiency of the implants was improved by the addition of a polymer membrane, which allowed a controlled release of anastrozole over a period of 400 days. [less ▲]

Detailed reference viewed: 18 (5 ULg)